USFR:NYE-WisdomTree Floating Rate Treasury Fund (USD)

ETF | Short Government |

Last Closing

USD 50.23

Change

0.00 (0.00)%

Market Cap

N/A

Volume

4.46M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Short Government

ETFs Containing USFR

RISN Inspire Tactical Balanced.. 19.29 % 0.00 %

N/A

USD 0.09B
CEW WisdomTree Emerging Curre.. 4.80 % 1.44 %

N/A

USD 7.52M
CEW WisdomTree Emerging Curre.. 4.80 % 0.55 %

N/A

USD 7.52M
GCC WisdomTree Continuous Com.. 4.74 % 0.75 %

N/A

USD 0.10B
PUTW WisdomTree CBOE S&P 500 P.. 4.17 % 0.38 %

N/A

USD 0.13B
USDU WisdomTree Bloomberg U.S... 4.13 % 0.50 %

N/A

USD 0.21B
FPE First Trust Preferred Sec.. 1.20 % 0.85 %

N/A

USD 5.65B
CYB 0.00 % 0.45 %

N/A

N/A
WTMF WisdomTree Managed Future.. 0.00 % 0.65 %

N/A

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Short Government) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 99.96% 100% F 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.96% 100% F 93% A
Trailing 12 Months  
Capital Gain 99.64% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.64% 100% F 92% A
Trailing 5 Years  
Capital Gain 100.52% 100% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 100.52% 100% F 84% B
Average Annual (5 Year Horizon)  
Capital Gain 0.91% N/A N/A 41% F
Dividend Return 2.84% N/A N/A 39% F
Total Return 1.93% N/A N/A 44% F
Risk Return Profile  
Volatility (Standard Deviation) 9.10% N/A N/A 80% B-
Risk Adjusted Return 31.22% N/A N/A 49% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike